Integrated Biopharma, Inc. splits its revenue 2 ways in its filings. By operating segments, the largest line in fiscal 2026, which ended Jun 30, 2026 was Contract Manufacturing at $42.4 million, 97% of the total. By sales mix, the largest line in fiscal 2026, which ended Jun 30, 2026 was Contract Manufacturing at $42.4 million, 97% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Jun 30, 2025
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2022
Jun 30, 2022
|
FY 2021
Jun 30, 2021
|
FY 2020
Jun 30, 2020
|
FY 2019
Jun 30, 2019
|
FY 2018
Jun 30, 2018
|
FY 2017
Jun 30, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
44
|
54
|
50
|
51
|
56
|
64
|
53
|
50
|
44
|
47
|
| Operating segments | ||||||||||
| Contract Manufacturing |
42
-18.0%
share 96.6%
|
52
+6.4%
share 95.1%
|
49
+0.6%
share 96.5%
|
48
-10.7%
share 95.3%
|
54
-12.5%
share 96.2%
|
62
share 97.3%
|
—
|
—
|
—
|
—
|
| Other Nutraceutical Business |
1
-44.4%
share 3.4%
|
3
+52.7%
share 4.9%
|
2
-27.0%
share 3.5%
|
2
+11.1%
share 4.7%
|
2
+25.0%
share 3.8%
|
2
share 2.7%
|
—
|
—
|
—
|
—
|
| Sales mix | ||||||||||
| Contract Manufacturing |
42
-18.0%
share 96.6%
|
52
+6.4%
share 95.1%
|
49
+0.6%
share 96.5%
|
48
-10.7%
share 95.3%
|
54
-12.5%
share 96.2%
|
62
share 97.3%
|
—
|
—
|
—
|
—
|
| Other Nutraceutical Business |
1
-44.4%
share 3.4%
|
3
+52.7%
share 4.9%
|
2
-27.0%
share 3.5%
|
2
+11.1%
share 4.7%
|
2
+25.0%
share 3.8%
|
2
share 2.7%
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INBP (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Hillside, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1016504
- Former names
- INTEGRATED HEALTH TECHNOLOGIES INC (until Apr 16, 2003); CHEM INTERNATIONAL INC (until May 14, 2002)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.